MS 436 CAS:1395084-25-9 is a potent and selective BRD4 bromodomain inhibitor (Ki of the first bromodomain (BRD4(1)) = 30 – 50 nM), MS436 exhibits in a panel of water-mediated interactions Low nanomolar affinity (estimated Ki is 30-50 nM), with 10-fold selectivity for BRD4(1) over BRD4(2). Blocks BRD4 transcriptional activity in lipopolysaccharide-induced nitric oxide and IL-6 production in mouse macrophages (IC50 values of 3.8 and 4.9 μM, respectively). Attenuates melanoma cell proliferation in vitro. MS436 represents a new class of bromodomain inhibitors that will facilitate further studies on the biological functions of the two bromodomains of BRD4 in gene expression.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
 
		 
		 
								 
								

![l-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-lHpyrazolo [3,4-d]pyrimidin-l-yl]-l-piperidinyl]-2-propyn-l-one](https://e1752fbe.rocketcdn.me/wp-content/uploads/AP14272-CAS-936563-91-6-1-e1686054563587.png)
![N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine](https://e1752fbe.rocketcdn.me/wp-content/uploads/AP14270-CAS-231278-20-9-1-e1686064939791.png)

